Newsroom

休斯頓--(BUSINESS WIRE)--(美國商業資訊)-- SLB (NYSE: SLB)今天公布了2025年第一季業績。 第一季業績 （單位：百萬美元，每股金額除外） 截至以下日期的三個月 變化 2025年 3月31日   2024年 12月31日   2024年 3月31日   較前一季   較去年同期 營收 $8,490 $9,284 $8,707 -9% -3% 稅前收入 - 按GAAP $1,063 $1,387 $1,357 -23% -22% 稅前收入利潤率 - 按GAAP 12.5% 14.9% 15.6% -241 bps -306 bps 歸屬於SLB的淨收入 - 按GAAP $797 $1,095 $1,068 -27% -25% 稀釋後每股盈餘 - 按GAAP $0.58 $0.77 $0.74 -25% -22%     調整後EBITDA* $2,020 $2,382 $2,057 -15% -2% 調整後EBITDA利潤率* 23.8% 25.7% 23.6% -186 bps 18 bps 稅前分部營業收入* $1,556 $1,918 $1,64...

休斯顿--(BUSINESS WIRE)--(美国商业资讯)-- SLB (NYSE: SLB)今天公布了2025年第一季度业绩。 第一季度业绩 （单位：百万美元，每股金额除外） 截至以下日期的三个月 变化 2025年 3月31日   2024年 12月31日   2024年 3月31日   环比   同比 营收 $8,490 $9,284 $8,707 -9% -3% 税前收入 - 基于GAAP $1,063 $1,387 $1,357 -23% -22% 税前收入利润率 - 基于GAAP 12.5% 14.9% 15.6% -241 bps -306 bps 归属于SLB的净收入 - 基于GAAP $797 $1,095 $1,068 -27% -25% 摊薄后每股收益 - 基于GAAP $0.58 $0.77 $0.74 -25% -22%     调整后EBITDA* $2,020 $2,382 $2,057 -15% -2% 调整后EBITDA利润率* 23.8% 25.7% 23.6% -186 bps 18 bps 税前分部营业收入* $1,556 $1,918 $1,6...

NEW ORLEANS--(BUSINESS WIRE)--Phixius by Nacha—a secure, peer-to-peer payment information network—announced today that ValidiFI is live on the Phixius network as an additional provider of bank account validation. Phixius now offers multiple providers of account validation, expanding the coverage of account validation data for Phixius users. "Phixius provides the connective tissue to reach multiple account validation service providers, addressing gaps in coverage for validating U.S. bank account...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced patient-reported outcomes following treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) that showed investigational drug UGN-102 (mitomycin) for intravesical solution achieved robust and durable complete response (CR) rates without ne...

HOUSTON--(BUSINESS WIRE)--SLB (NYSE: SLB) hat heute die Ergebnisse für das erste Quartal 2025 bekannt gegeben. Ergebnisse des ersten Quartals (Angaben in Millionen, außer bei Beträgen pro Aktie) Drei Monate bis Änderung 31. März 2025   31. Dez. 2024   31. März 2024   Vorquartal   Vorjahr Umsatz $8.490 $9.284 $8.707 -9% -3% Gewinn vor Steuern- GAAP-Basis $1.063 $1.387 $1.357 -23% -22% Marge Gewinn vor Steuern - GAAP-Basis 12,5% 14,9% 15,6% -241 bps -306 bps Auf SLB entfallender Nettogewinn - GAA...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced new data from the OPTIMA II Phase 2b study of UGN‑102 (mitomycin) for intravesical solution demonstrate clinically meaningful two-year duration of response (24.2 months) by Kaplan-Meier analysis. UGN-102 is UroGen’s sustained-release formulation of mitomycin being developed for the tre...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers and acquirers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024 and February 25, 2025. Geron is a commercial-stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Gero...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with stage III or IVA, resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Results at the first interim analysis of the trial showed KEYTRUDA significantly improved event-free survival (EFS) as pa...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Fluence Energy, Inc. (NASDAQ: FLNC) between November 29, 2023 and February 10, 2025. Fluence describes itself as a company that “offers energy storage products and solutions, delivery services, recurring operational and maintenance services, and digital applications and solutions for energy storage and other power asse...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Ready Capital Corporation (NYSE: RC) between November 7, 2024 and March 2, 2025. Ready Capital describes itself as a real estate finance company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Read...